Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations

Transplantation

Volumn 95, Issue 8, 2013, Pages 1015-1020

  Gracia Ahufinger, Irene ^a   Gutiérrez Aroca, Juan ^a   Cordero, Elisa ^b   Vidal, Elisa ^a   Cantisán, Sara ^a   Del Castillo, Domingo ^a   Martín Gandul, Cecilia ^b   Rivero, Antonio ^a   Torre Cisneros, Julián ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Cytomegalovirus; Resistance antiviral agents; Solid organ transplantation

Indexed keywords

CORTICOSTEROID; CREATININE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; ANTIVIRAL RESISTANCE; CLINICAL ARTICLE; CREATININE CLEARANCE; CYSTIC FIBROSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GENE MUTATION; GENOTYPE; GLOMERULONEPHRITIS; GRAFT REJECTION; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MEDICAL DECISION MAKING; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; FEMALE; GANCICLOVIR; GENES, VIRAL; HUMANS; MALE; MIDDLE AGED; MUTATION; ORGAN TRANSPLANTATION; VIRAL LOAD; VIRUS REPLICATION;

EID: 84876691654     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31828555ac     Document Type: Review

References (23)

1. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779.
2. de la Torre-Cisneros J, Farinas MC, Caston JJ, et al. GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. Enferm Infecc Microbiol Clin 2011; 29: 735.
3. Avery RK. Update in management of ganciclovir-resistant cytomega-lovirus infection.Curr Opin Infect Dis 2008;21: 433.
4. Boivin G, Goyette N, Rollag H, et al. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther 2009; 14: 697.
5. Limaye AP, Raghu G, Koelle DM, et al. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185: 20.
6. Angeles Marcos M. Resistance studies: when are they indicated?. Enferm Infecc Microbiol Clin 2011; 29 Suppl 6: 24.
7. Chou S. Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Antimicrob Agents Che-mother 2010; 54: 2371.
8. Iwasenko JM, Scott GM, Ziegler JB, et al. Emergence and persistence of multiple antiviral-resistant CMV strains in a highly immunocom-promised child. J Clin Virol 2007; 40: 152.
9. Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645.
10. Wolf DG, Yaniv I, Honigman A, et al. Early emergence of ganciclovir-resistant human cytomegalovirus strains in children with primary combined immunodeficiency. J Infect Dis 1998; 178: 535.
11. Chou S, Lurain NS, Thompson KD, et al. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis 2003; 188: 32.
12. Chou S, Waldemer RH, Senters AE, et al. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis 2002; 185: 162.
13. Chou S, Van Wechel LC, Lichy HM, et al. Phenotyping of cytomeg-alovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob Agents Chemother 2005; 49: 2710.
14. Boivin G, Goyette N, Farhan M, et al. Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis. J Clin Virol 2012; 53: 208.
15. Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 2002; 35: 866.
16. Couzi L, Helou S, Bachelet T, et al. High incidence of antic-ytomegalovirus drug resistance among D+R-kidney transplant recipients receiving preemptive therapy. Am J Transplant 2012; 12: 202.
17. Boivin G, Goyette N, Gilbert C, et al. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl Infect Dis 2005; 7: 166.
18. Isada CM, Yen-Lieberman B, Lurain NS, et al. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cy-tomegalovirus infection. Transpl Infect Dis 2002; 4: 189.
19. Eid AJ, Razonable RR. New developments in the management of cy-tomegalovirus infection after solid organ transplantation. Drugs 2010; 70: 965.
20. Iwasenko JM, Scott GM, Naing Z, et al. Diversity of antiviral-resistant human cytomegalovirus in heart and lung transplant recipients. Transpl Infect Dis 2011; 13: 145.
21. Boivin G, Goyette N, Gilbert C, et al. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. J Med Virol 2005; 77: 425.
22. Boivin G, Chou S, Quirk MR, et al. Detection of ganciclovir resistance mutations quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease. J Infect Dis 1996; 173: 523.
23. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalo-virus. Clin Microbiol Rev 2010; 23: 689.